Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Nello Mainolfi

Kymera Therapeutics, Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Metric
Company Name	Kymera Therapeutics, Inc.
Symbol	KYMR
MSH ID	COM:KYMERATX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	186
Website	kymeratx.com
LinkedIn
Founders

Metric
Market Cap	2.22B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	78.59M
Revenue (LTM)
Revenue (NTM)
Gross Profit	75.03M
EBITDA	-143.20M
Operating Income	-165.53M
Net Income	-146.96M
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.97
Operating Profit Margin	-2.04
EBITDA Margin	-1.82
Net Profit Margin	-1.78
Return on Equity	-0.29
Return on Assets	-0.18
Return on Capital Employed	-0.21

COM:KYMERATX

Kymera Therapeutics, Inc.

Last Close

32.89

10/03 20:00

Market Cap

2.14B

Beta: -

Volume Today

755.31K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-12.25
P/B Ratio	5.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	36.61
EV Multiple	-11.47

Metric
Days Sales Outstanding	29.44
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	87.14
Cash Conversion Cycle	-453.02
Asset Turnover	0.14

Metric
Operating Cash Flow	-102.83M
Free Cash Flow	-137.31M
Cash Flow to Debt	-1.13
Operating Cash Flow/Sales	-1.20
Free Cash Flow Yield	-0.09

Metric
Cash & Equivalents	109.97M
Accounts Receivable	-15M
Inventory
Goodwill
Debt to Capitalization	0.18
Debt to Assets	0.15
Current Ratio	5.95
Quick Ratio	9.57

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.88
R&D to Revenue	3.83
SG&A to Revenue	1.12